American Journal of Hematology · 2016 · 89 citations · 28 references
MedicineHematologyOncologyEpidemiologyHematologic OncologyRisk AssessmentHematologic MalignanciesModel EvaluationThromboembolic DiseaseThromboembolism PreventionThrombosisVenous ThromboembolismClinical Risk ScoresRisk Prediction ScoresRisk Score DevelopmentThromboembolic Risk StratificationThromboembolism Risk PredictionThromboprophylaxis In Cancer PatientsThromboprophylaxis In Medical InpatientsVenous Thromboembolism Assessment
Lymphoma patients are at increased risk of thromboembolic events but thromboprophylaxis in these patients is largely underused. We sought to develop and validate a simple model, based on individual clinical and laboratory patient characteristics that would designate lymphoma patients at risk for thromboembolic event. The study population included 1,820 lymphoma patients who were treated in the Lymphoma Departments at the Clinics of Hematology, Clinical Center of Serbia and Clinical Center Kragujevac. The model was developed using data from a derivation cohort (n = 1,236), and further assessed in the validation cohort (n = 584). Sixty-five patients (5.3%) in the derivation cohort and 34 (5.8%) patients in the validation cohort developed thromboembolic events. The variables independently associated with risk for thromboembolism were: previous venous and/or arterial events, mediastinal involvement, BMI>30 kg/m(2) , reduced mobility, extranodal localization, development of neutropenia and hemoglobin level < 100g/L. Based on the risk model score, the population was divided into the following risk categories: low (score 0-1), intermediate (score 2-3), and high (score >3). For patients classified at risk (intermediate and high-risk scores), the model produced negative predictive value of 98.5%, positive predictive value of 25.1%, sensitivity of 75.4%, and specificity of 87.5%. A high-risk score had positive predictive value of 65.2%. The diagnostic performance measures retained similar values in the validation cohort. Developed prognostic Thrombosis Lymphoma - ThroLy score is more specific for lymphoma patients than any other available score targeting thrombosis in cancer patients. Am. J. Hematol. 91:1014-1019, 2016. © 2016 Wiley Periodicals, Inc.
28
Prevention of Venous Thromboembolism
William Geerts, John A. Heit, Charles Marc Samama · CHEST Journal · 2008 · 3.8K citations
Gary S. Collins, Johannes B. Reitsma, Douglas G. Altman et al. · Annals of Internal Medicine · 2015 · 2.9K citations · Full text
Prevention of VTE in Nonsurgical Patients
Susan R. Kahn, Wendy Lim, Andrew Dunn et al. · CHEST Journal · 2012 · 2.7K citations · Full text
Development and validation of a predictive model for chemotherapy-associated thrombosis
Alok A. Khorana, Nicole M. Kuderer, Eva Culakova et al. · Blood · 2008 · 2.2K citations · Full text
Medicine, Hematology, Oncology +14